

Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of claims, in the application.

Listing of Claims

1. (Currently Amended) A method of ameliorating chronic allograft rejection in a human or animal allograft recipient comprising administering to the recipient in need of such treatment, in combination, a therapeutically effective amount of cyclosporin at least once weekly and a therapeutically effective amount of 2-chlorodeoxyadenosine at least once weekly, wherein chronic allograft rejection is determined by histological examination and amelioration is associated with no more than mild lymphocyte infiltration in the myocardium and limited transplant arteriosclerosis.
2. (Original) The method according to claim 1 wherein the therapeutically effective amount of cyclosporin is between about seven and about 224 times the amount by mass of 2-chlorodeoxyadenosine.
3. (Original) The method according to claim 1 wherein the therapeutically effective amount of cyclosporin is between about 1 mg and about 16 mg per kilogram of recipient body mass per day.
4. (Original) The method according to claim 3 wherein the dosing regime for cyclosporin is between about 7 and about 112 mg per kilogram of recipient body mass per week.
5. (Original) The method according to claim 4 wherein the dosing regime for cyclosporin is about 5 mg per kilogram of recipient body mass per day for about two weeks followed by about 5 mg per kilogram of recipient body mass about three times per week.
6. (Original) The method according to claim 5 wherein the daily dose is divided into two equal daily doses.

7. (Previously Presented) The method according to claim 1 wherein the therapeutically effective amount of 2-chlorodeoxyadenosine is between about 0.5 mg and about 3 mg per kilogram of recipient body mass per week.
8. (Previously Presented) The method according to claim 1 wherein the therapeutically effective amount of 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.
9. (Original) The method according to claim 7 wherein the dosing regime for 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.
10. (Previously Presented) The method according to claim 7 wherein the dosing regime for 2-chlorodeoxyadenosine is about 3 mg per kilogram of recipient body mass about every three weeks.
11. (Original) The method according to claim 7 wherein the dosing regime for 2-chlorodeoxyadenosine is 1.5 mg per kilogram of recipient body mass about every three weeks.
12. (Original) The method according to claim 1 wherein the mode of administration of cyclosporin and 2-chlorodeoxyadenosine is subcutaneously, orally, or intravenously.
13. (Currently Amended) A method of preventing chronic allograft rejection in an allograft recipient comprising administering to an allograft recipient a therapeutically effective amount of cyclosporin at least once weekly and a therapeutically effective amount of 2-chlorodeoxyadenosine at least once weekly, wherein chronic allograft rejection is determined by histological examination and prevention is associated with no more than mild lymphocyte infiltration in the myocardium and limited transplant arteriosclerosis.
14. (Previously Presented) The method according to claim 13 wherein the therapeutically effective amount of cyclosporin is between about 2 and about 224 times the amount by weight of 2-chlorodeoxyadenosine.

15. (Previously Presented) The method according to claim 13 wherein the therapeutically effective amount of cyclosporin is between about 1 mg and about 16 mg per kilogram of recipient body mass per day administered daily.
16. (Original) The method according to claim 13 wherein the dosing regime for cyclosporin is between about 7 and about 112 mg per kilogram of recipient body mass per week.
17. (Original) The method according to claim 16 wherein the dosing regime for cyclosporin is about 5 mg per kilogram of recipient body mass per day for about two weeks followed by about 5 mg per kilogram of recipient body mass about three times per week.
18. (Original) The method according to claim 17 wherein the daily dose is divided into two equal daily doses.
19. (Previously Presented) The method according to claim 13 wherein the therapeutically effective amount of 2-chlorodeoxyadenosine is between about 0.5 mg and about 3 mg per kilogram of recipient body mass per week.
20. (Previously Presented) The method according to claim 13 wherein the therapeutically effective amount of 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.
21. (Original) The method according to claim 20 wherein the dosing regime for 2-chlorodeoxyadenosine is 1 mg per kilogram of recipient body mass per week.
22. (Previously Presented) The method according to claim 20 wherein the dosing regime for 2-chlorodeoxyadenosine is about 3 mg per kilogram of recipient body mass about three weeks.
23. (Original) The method according to claim 20 wherein the dosing regime for 2-chlorodeoxyadenosine is 1.5 mg per kilogram of recipient body mass about every three weeks.

24. (Original) The method according to claim 13 wherein the mode of administration of cyclosporin and 2-chlorodeoxyadenosine is subcutaneously, orally, or intravenously.

Claims 25 - 36. (Cancelled)